Related Experiment Video
Updated: Apr 17, 2026
Pooled shRNA Library Screening to Identify Factors that Modulate a Drug Resistance Phenotype
Published on: June 17, 2022
Mechanism-Driven Repurposing of All-Trans Retinoic Acid (ATRA) for AML1-MTG16⁺ Acute Myeloid Leukemia: A
Kuangguo Zhou1, Zhiqiong Wang1, Jie Xiong1
1Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China.
Background:
Acute myeloid leukemia (AML) with rare aberrations like AML1-MTG16 fusion encounters precision oncology challenges, exacerbated by the "Long-Tail" dilemma. Preclinical data show all-trans retinoic acid (ATRA) restores myeloid differentiation in MTG16-deficient AML models, but its clinical translation remains unexplored.
Case Presentation:
We treated a 73-year-old unfit AML patient with early molecular progression (AML1-MTG16 burden elevated to 0.2%) using ATRA plus azacitidine/venetoclax. Sustained measurable residual disease-negative remission (21 months) and undetectable fusion transcripts were achieved with only grade 2 neutropenia.
Conclusions:
This case may preliminarily suggest ATRA's potential in AML1-MTG16⁺ AML, offering translational clues for ultra-rare leukemia subtypes, pending further validation.
More Related Videos
07:38Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants
Published on: June 6, 2025
09:16Investigation of the Transcriptional Role of a RUNX1 Intronic Silencer by CRISPR/Cas9 Ribonucleoprotein in Acute Myeloid Leukemia Cells
Published on: September 1, 2019